In a recent study, a polypill, including metformin, aspirin, simvastatin, and angiotensin-converting enzyme inhibitors, was administered in a mixed murine model of Alzheimer’s disease and type 2 diabetes, showing promising results in ameliorating metabolic parameters, cognitive impairment, brain atrophy, neuronal and synaptic loss, amyloid burden, tau phosphorylation, central inflammation and central spontaneous bleeding [122]. This evidence concerns the gene MAPT and Alzheimer disease.